🇺🇸 FDA
Patent

US 11458126

DHODH inhibitor for use in treating hematologic cancers

granted A61KA61K31/437A61K31/53

Quick answer

US patent 11458126 (DHODH inhibitor for use in treating hematologic cancers) held by PTC THERAPEUTICS, INC. expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PTC THERAPEUTICS, INC.
Grant date
Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/437, A61K31/53, A61K9/0053, A61P